Amgen Inc.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world, and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Available Agents
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases, and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience, and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Available Agents
Bayer
Bayer is a global, Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
Bayer’s brands treat and prevent conditions to improve quality of life. Bayer Pharmaceuticals is committed to meeting the needs of patients in our therapeutic areas of focus. We focus on researching, developing, and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology.
For more information, please visit www.bayer.us
Available Agents
Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) has a vision for the future of cancer care that is focused on Immuno- Oncology, now considered a major treatment choice alongside surgery, radiation, chemotherapy and targeted therapies for certain types of cancer.
BMS has a comprehensive clinical portfolio of investigational and approved Immuno-Oncology agents, many of which were discovered and developed by their scientists. The ongoing Immuno-Oncology clinical program at BMS is looking at broad patient populations, across multiple solid tumors and hematologic malignancies. The program is studying a variety of lines of therapy and histologies, with the intent of powering trials for overall survival and other important measures like durability of response. BMS pioneered the research leading to the first regulatory approval for the combination of two Immuno-Oncology agents and continue to study the role of combinations in cancer.
BMS is also investigating other immune system pathways in the treatment of cancer, including CTLA-4, CD-137, KIR, SLAMF7, PD-1, GITR, CSF1R, IDO, and LAG-3. These pathways may lead to potential new treatment options — in combination or monotherapy — to help patients fight different types of cancers. Collaboration with academia, as well as small and large biotech and pharmaceutical companies, to research the potential of Immuno-Oncology and non-Immuno-Oncology combinations helps BMS to achieve their goal of providing new treatment options in clinical practice.
Bristol-Myers Squibb is committed to changing survival expectations in hard-to-treat cancers and the way patients live with cancer.
Available Agents
EMD Serono, Inc.
EMD Serono, Inc. is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany and in the U.S. EMD Serono, Inc. has expertise in several therapeutic areas and products including neurology and immunology, endocrinology, oncology, and fertility.
Available Agents
Genentech, a Member of the Roche Group
Founded 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. Genentech has the largest biotech research center in the world and we market approximately 40 medicines, including 13 medicines for cancer. We are testing new medicines with the hope of helping people with serious diseases live longer and better lives and are committed to developing personalized medicines and getting the right medicine to the right patient.
The company, a member of the Roche Group, has headquarters in South San Francisco, California.
Available Agents
- Alectinib
- Atezolizumab
- Bevacizumab
- Cobimetinib
- Giredestrant
- Inavolisib
- Obinutuzumab
- Pertuzumab
- Pertuzumab/trastuzumab/hyaluronidase-zzxf
- Tiragolumab
- Trastuzumab
- Trastuzumab and hyaluronidase-oysk
Genentech supports non-clinical research proposals through a separate mechanism. Please visit Genentech's Outgoing Material Transfer Agreement (MTA) Program to submit a request for a Genentech agent for non-clinical work.
Kyowa Hakko Kirin Co., Ltd.
Kyowa Hakko Kirin is an R&D-based life sciences company with special strengths in biotechnology. The novel drug discovery of Kyowa Hakko Kirin is firmly supported by the exquisite experience and technologies in research, development and manufacture of biologics, and by open innovation. The distinguished fundamental technologies of Kyowa Hakko Kirin are characterized by POTELLIGENT® and human-antibody producing technologies which we successfully established, and contribute to efficient production of therapeutic antibodies.
Kyowa Hakko Kirin will be a Japan-based Global Specialty Pharmaceutical Company who contributes to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
Available Agents
SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company that applies a precision medicine approach to acquiring, developing, and commercializing life-changing medicines.
Available Agents
Syntrix Biosystems, Inc.
Syntrix Biosystems, Inc. is a biopharmaceutical company focusing on the discovery and development of novel therapeutics in oncology, pain, and autoimmunity.
Available Agents
Xcovery Holding Company LLC
Xcovery is a biopharmacceutical company dedicated to the development of next generation kinase inhibitors for the treatment of cancer.